var data={"title":"Terbinafine (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Terbinafine (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/8195?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=terbinafine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Terbinafine (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=terbinafine-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Terbinafine (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9566188\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>LamISIL;</li>\n      <li>Terbinex [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9480131\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Terbinafine;</li>\n      <li>Auro-Terbinafine;</li>\n      <li>CO Terbinafine;</li>\n      <li>Dom-Terbinafine;</li>\n      <li>GD-Terbinafine;</li>\n      <li>JAMP-Terbinafine;</li>\n      <li>Lamisil;</li>\n      <li>Mylan-Terbinafine;</li>\n      <li>PHL-Terbinafine;</li>\n      <li>PMS-Terbinafine;</li>\n      <li>Q-Terbinafine;</li>\n      <li>Riva-Terbinafine;</li>\n      <li>Sandoz-Terbinafine;</li>\n      <li>Teva-Terbinafine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10526800\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=terbinafine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Terbinafine (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tinea capitis:</b> Children &ge;4 years and Adolescents: Oral: Granules:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;25 kg: 125 mg once daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">25 to 35 kg: 187.5 mg once daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;35 kg: 250 mg once daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Onychomycosis</b> (Gupta 1997): Limited data available: Children and Adolescents: Oral: Tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 to 20 kg: 62.5 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 to 40 kg: 125 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: 250 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Onychomycosis:</b> Oral: Tablet: Fingernail: 250 mg once daily for 6 weeks; Toenail: 250 mg once daily for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Missed doses:</i> If a dose is missed, take as soon as remembered, unless it is less than 4 hours before the next dose is due.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tinea capitis: </b>Patients &gt;35 kg: Oral: Granules: 250 mg once daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, clearance is decreased ~50% in adult patients with CrCl &le;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Granules: Children &ge;4 years, Adolescents, and Adults: Use is contraindicated in chronic or active hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets: Adults: Use is contraindicated in chronic or active hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247741\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Terbinex: 250 mg &amp; 1% [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LamISIL: 125 mg (1 ea [DSC], 14 ea [DSC]); 187.5 mg (1 ea [DSC], 14 ea [DSC]) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LamISIL: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9566193\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24525299\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=terbinafine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Terbinafine (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Terbinex Kit contains terbinafine 250 mg tablets and hydroxypropyl-chitosan 1% nail lacquer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50624329\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Lamisil granules have been discontinued in the United States for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49037895\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Lamisil: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM524717.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//CovC0x0ey2BbNY46aAsKLBP/BsAitBmX3QpPKyuyT5w==&amp;TOPIC_ID=15936\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM524717.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10526801\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets may be administered without regard to meals. Granules should be taken with food; sprinkle on a spoonful of nonacidic food (eg, pudding, mashed potatoes); do not use applesauce or fruit-based foods; swallow granules whole without chewing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567979\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granules: Store at  25&deg;C (77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store below 25&deg;C (77&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10526790\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granules: Treatment of tinea capitis (FDA approved in ages &ge;4 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Treatment of onychomycosis of the toenail or fingernail due to susceptible dermatophytes (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9566184\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Terbinafine may be confused with terbutaline </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LamISIL may be confused with LaMICtal, Lomotil</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567972\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash (less common in children), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (children), diarrhea, dysgeusia (may be severe and result in weight loss, anxiety, and depression), dyspepsia, nausea, pharyngolaryngeal pain (children), toothache (children), upper abdominal pain (children), vomiting (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Liver enzyme disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Influenza (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Decreased visual acuity (children), vision color changes (children; color confusion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (children), nasal congestion (children), nasopharyngitis (children), rhinorrhea (children), upper respiratory tract infection (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute generalized exanthematous pustulosis, ageusia, agranulocytosis, alopecia, altered sense of smell, anaphylaxis, anemia, angioedema, anosmia, anxiety, arthralgia, auditory impairment, bullous dermatitis, cholestasis, cutaneous lupus erythematosus, depression, DRESS syndrome, erythema multiforme, exacerbation of psoriasis, exacerbation of systemic lupus erythematosus, exfoliative dermatitis, fatigue, flu-like symptoms, hemolytic-uremic syndrome, hepatic insufficiency, hepatic failure, hepatitis, hypersensitivity reaction, hypoesthesia, increased creatine phosphokinase, lens disease, malaise, myalgia, pancreatitis, pancytopenia, paresthesia, psoriasiform eruption, retinopathy, rhabdomyolysis, serum sickness-like reaction, severe neutropenia, skin photosensitivity, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombocytopenia, thrombotic thrombocytopenic purpura, tinnitus, toxic epidermal necrolysis, vasculitis, vertigo, visual field defect</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247745\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Hypersensitivity to terbinafine or any component of the formulation; chronic or active hepatic disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247730\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allylamine antifungal hypersensitivity: Use caution in patients sensitive to allylamine antifungals (eg, naftifine, butenafine); cross-sensitivity to terbinafine may exist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Has been reported with use; instruct patients to report depressive symptoms/mood changes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Taste disturbance (including loss of taste) may occur and severe cases resulting in decreased food intake, weight loss, anxiety or depression have been reported; resolution may be delayed (eg, several weeks to &gt;1 year) following discontinuation of therapy or in some cases, disturbance may be permanent. Discontinue therapy in patients with symptoms of taste disturbance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Transient decreases in absolute lymphocyte counts were observed in clinical trials; severe neutropenia (reversible upon discontinuation) has also been reported. Monitor CBC in patients with preexisting immunosuppression if therapy is to continue &gt;6 weeks. Discontinue therapy if ANC &le;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic failure: Cases of hepatic failure, some leading to liver transplant or death, have been reported. May occur in patients with and without preexisting hepatic disease; severity of hepatic events and/or outcomes may be worse in patients with active or chronic hepatic disease. Perform baseline and periodic liver function tests; discontinue use if clinical evidence of liver injury develops (eg, nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, pale stools) or elevated liver function tests occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious skin and hypersensitivity reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome) have occurred. If progressive skin rash or signs and symptoms of a hypersensitivity reaction occur, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Although rare, changes in the ocular lens and retina have been reported; discontinuation of therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory effects: Smell disturbance (including loss of smell) has been reported; resolution may be delayed (eg, &gt;1 year) following discontinuation of therapy or in some cases, disturbance may be permanent. Discontinue therapy in patients with symptoms of smell disturbance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, have been reported (some fatal). Discontinue if TMA occurs; consider diagnosis of TMA with unexplained thrombocytopenia and anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disease (Lupus): Precipitation or exacerbation of cutaneous or systemic lupus erythematosus has been observed; discontinue if signs and/or symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use is contraindicated in patients with active or chronic hepatic disease; clearance is reduced by ~50% in hepatic cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal dysfunction (CrCl &le;50 mL/minute); clearance is reduced by ~50%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Due to potential toxicity, confirmation of diagnostic testing of nail or skin specimens prior to treatment of onychomycosis or dermatomycosis is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567975\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247734\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15936&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amitriptyline: Terbinafine (Systemic) may increase the serum concentration of Amitriptyline.  Management: Monitor for increased effects/toxicity of amitriptyline during concomitant administration with terbinafine. Reduced dosages of amitriptyline may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Tamoxifen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desipramine: Terbinafine (Systemic) may increase the serum concentration of Desipramine.  Management: Monitor for increased effects/toxicity of desipramine during concomitant administration with terbinafine. Reduced dosages of desipramine may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imipramine: Terbinafine (Systemic) may increase the serum concentration of Imipramine.  Management: Monitor for increased effects/toxicity of imipramine during concomitant administration with terbinafine. Reduced dosages of imipramine may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nortriptyline: Terbinafine (Systemic) may increase the serum concentration of Nortriptyline.  Management: Monitor for increased effects/toxicity of nortriptyline during concomitant administration with terbinafine. Reduced dosages of nortriptyline may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Terbinafine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247736\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247747\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Avoid use in pregnancy since treatment of onychomycosis is postponable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10526802\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">AST/ALT prior to initiation, repeat if used &gt;6 weeks; CBC (if used &gt;6 weeks in immunosuppressed patients)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247728\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Synthetic allylamine derivative that inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This results in a deficiency in ergosterol within the fungal cell membrane and results in fungal cell death.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247744\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Children and Adults: &gt;70% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributed to sebum and skin predominantly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Plasma: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic predominantly via CYP1A2, 3A4, 2C8, 2C9, and 2C19 to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Children 36% to 64%; Adults: 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal half-life: 200 to 400 hours; very slow release of drug from skin and adipose tissues occurs; effective half-life: Children: 27 to 31 hours; Adults: ~36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Children and Adults: Within 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80%, primarily as inactive metabolites); feces (20%) (Debruyne 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Children (14 to 68 kg): 15.6 to 26.7 L/hour </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10806645\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 25 mg/mL oral suspension may be made using tablets. Crush twenty 250 mg tablets and reduce to a fine powder. Add small amount of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; and mix to a uniform paste; mix while adding the vehicle in geometric proportions to <b>almost</b> 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable 42 days.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9574689\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LamISIL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $978.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Terbinafine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $383.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390206\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amizil (PH);</li>\n      <li>Antifin (CN, PK);</li>\n      <li>Atifan (CZ, EE);</li>\n      <li>Camisan (MY);</li>\n      <li>Cutis (LK);</li>\n      <li>Deolate (NZ);</li>\n      <li>Derfin (BD);</li>\n      <li>Dermafin (MY);</li>\n      <li>Dermasil (IL);</li>\n      <li>Dermatin (DE);</li>\n      <li>Dermax (ZA);</li>\n      <li>Dicil (EC);</li>\n      <li>EU2000 (TH);</li>\n      <li>Finex (PY);</li>\n      <li>Fungasil (MT);</li>\n      <li>Funginix (DK);</li>\n      <li>Fungitech (TW);</li>\n      <li>Fungizid (DE);</li>\n      <li>Fungster (BE);</li>\n      <li>Funhotek (UA);</li>\n      <li>Funzal (CO);</li>\n      <li>Interbi (HK, ID);</li>\n      <li>L:isim (MY, SG);</li>\n      <li>Lamifen (AE, JO, PH, QA, SA);</li>\n      <li>Lamisil (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, OM, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZM, ZW);</li>\n      <li>Lamisil AT (ID);</li>\n      <li>Lamisil Dermgel (FR, IL);</li>\n      <li>Lamisil Once (AE, AU, HK, KR, KW, LB, PH, QA, SA, TH, VN);</li>\n      <li>Lamisilate (FR);</li>\n      <li>Lamizyl (UA);</li>\n      <li>Lammifen (KW);</li>\n      <li>Lapiderm (KR);</li>\n      <li>Micoset (CL);</li>\n      <li>Micozone (EC);</li>\n      <li>Muzona (HK);</li>\n      <li>Mycelvan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Nailderm (IE);</li>\n      <li>Patir (IL);</li>\n      <li>Periafin (TW);</li>\n      <li>Ronasil Derm Gel (KR);</li>\n      <li>Sebifin (IN);</li>\n      <li>Skinabin (BD);</li>\n      <li>SolvEasy Tinea Cream (AU);</li>\n      <li>Tamsil (AU);</li>\n      <li>Tenabin (KR);</li>\n      <li>Terbex (BD);</li>\n      <li>Terbifin (BD, HK);</li>\n      <li>Terbihexal (AU);</li>\n      <li>Terbix (CR, DO, GT, HN, NI, PA);</li>\n      <li>Terekol (AR);</li>\n      <li>Terfex (VE);</li>\n      <li>Terfine (TW);</li>\n      <li>Terfung (TW);</li>\n      <li>Tiersil Once (KR);</li>\n      <li>Zabel (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdel-Rahman SM and Nahata MC, &ldquo;Oral Terbinafine: A New Antifungal Agent,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(4):445-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9101008/pubmed\" target=\"_blank\" id=\"9101008\">9101008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abdel-Rahman SM, Herron J, Fallon-Friedlander S, et al, &quot;Pharmacokinetics of Terbinafine in Young Children Treated for Tinea Capitis,&quot; <i>Pediatr Infect Dis J</i>, 2005, 24(10):886-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/16220086/pubmed\" target=\"_blank\" id=\"16220086\">16220086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amichai B and Grunwald MH, &ldquo;Adverse Drug Reactions of the New Oral Antifungal Agents - Terbinafine, Fluconazole, and Itraconazole,&rdquo; <i>Int J Dermatol</i>, 1998, 37(6):410-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9646122/pubmed\" target=\"_blank\" id=\"9646122\">9646122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angello JT, Voytovich RM, and Jan SA, &ldquo;A Cost/Efficacy Analysis of Oral Antifungals Indicated for the Treatment of Onychomycosis: Griseofulvin, Itraconazole, and Terbinafine,&rdquo; <i>Am J Manag Care</i>, 1997, 3(3):443-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/10173095/pubmed\" target=\"_blank\" id=\"10173095\">10173095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Backer M, De Vroey C, Lesaffre E, et al, &ldquo;Twelve Weeks of Continuous Oral Therapy for Toenail Onychomycosis Caused by Dermatophytes: A Double-Blind Comparative Trial of Terbinafine 250 mg/day Versus Itraconazole 200 mg/day,&rdquo; <i>J Am Acad Dermatol</i>, 1998, 38(5 Pt 3):S57-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9594939/pubmed\" target=\"_blank\" id=\"9594939\">9594939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. <i>Clin Pharmacokinet</i>. 2001;40(6):441-472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/11475469/pubmed\" target=\"_blank\" id=\"11475469\">11475469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dwyer CM, White MI, and Sinclair TS, &ldquo;Cholestatic Jaundice Due to Terbinafine,&rdquo; <i>Br J Dermatol</i>, 1997, 136(6):976-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9217846/pubmed\" target=\"_blank\" id=\"9217846\">9217846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedlander SF, Aly R, Krafchik B, et al, &ldquo;Terbinafine in the Treatment of <i>Trichophyton</i> Tinea Capitis: A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study,&rdquo; <i>Pediatrics</i>, 2002, 109(4):602-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/11927703/pubmed\" target=\"_blank\" id=\"11927703\">11927703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta AK and Shear NH, &ldquo;Terbinafine: An Update,&rdquo; <i>J Am Acad Dermatol</i>, 1997, 37(6):979-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9418768/pubmed\" target=\"_blank\" id=\"9418768\">9418768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta AK, Sibbald RG, Knowles SR, et al, &ldquo;Terbinafine Therapy May Be Associated With the Development of Psoriasis De Novo or Its Exacerbation: Four Case Reports and a Review of Drug Induced Psoriasis,&rdquo; <i>J Am Acad Dermatol</i>, 1997, 36(5 Part 2):858-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9146568/pubmed\" target=\"_blank\" id=\"9146568\">9146568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta AK, Sibbald RG, Lynde CW, et al, &ldquo;Onychomycosis in Children: Prevalence and Treatment Strategies,&rdquo; <i>J Am Acad Dermatol</i>, 1997, 36(3 Pt 1):395-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9091470/pubmed\" target=\"_blank\" id=\"9091470\">9091470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones TC, &ldquo;Overview of the Use of Terbinafine in Children,&rdquo; <i>Br J Dermatol</i>, 1995, 132(5):683-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/7772471/pubmed\" target=\"_blank\" id=\"7772471\">7772471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamisil tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamisil granules [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trepanier EF and Amsden GW, &ldquo;Current Issues in Onychomycosis,&rdquo; <i>Ann Pharmacother</i>, 1998, 32(2):204-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/9496407/pubmed\" target=\"_blank\" id=\"9496407\">9496407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vickers AE, Sinclair JR, Zollinger M, et al, &quot;Multiple Cytochrome P-450s Involved in the Metabolism of Terbinafine Suggest a Limited Potential for Drug-Drug Interactions,&quot; <i>Drug Metab Dispos</i>, 1999, 27(9):1029-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-pediatric-drug-information/abstract-text/10460803/pubmed\" target=\"_blank\" id=\"10460803\">10460803</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15936 Version 159.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9566188\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9480131\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10526800\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F247741\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9566193\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F24525299\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50624329\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49037895\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10526801\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9567979\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10526790\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9566184\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9567972\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F247745\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F247730\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9567975\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F247734\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F247736\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F247747\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10526802\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F247728\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F247744\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10806645\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9574689\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390206\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15936|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=terbinafine-systemic-drug-information\" class=\"drug drug_general\">Terbinafine (systemic): Drug information</a></li><li><a href=\"topic.htm?path=terbinafine-systemic-patient-drug-information\" class=\"drug drug_patient\">Terbinafine (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}